Read by QxMD icon Read


Bokanda Ekoko Eric, Ekomane Emile, Kenfack Nguemo Gatien Romuald, Njilah Konfor Isaac, Ashukem Nkongho Ethel, Tematio Paul, Bisse Salomon Betrant, Ngueutchoua Gabriel, Orock Ngui Shelly, Belinga Belinga Cedric
Petrography, heavy mineral and trace element geochemistry have been used to unravel the tectonic setting, source area lithology, diagenesis and paleoclimate conditions of the Mamfe sandstones. Quartz exists as monocrystalline (79%), and polycrystalline grains (21%). Orthoclase and microcline are the most dominant feldspars in the rocks. Heavy minerals such as zircon, tourmaline, kyanite, augite, garnets, hornblende, epidotes, diopside, muscovites, biotites, and opaque minerals were disclosed by the samples after bromoform separation...
February 2019: Heliyon
Jingmei Xie, Ning Wan, Zhuoru Liang, Tiantian Zhang, Jie Jiang
Ixazomib, as a proteasome inhibitor, inhibits the chymotrypsin-like activity of the β5 subunit of the 20S proteasome. Based on the TOURMALINE-MM1 study, ixazomib was proved by the FDA as the orphan drug in November 2015. With a promising effect in prolonging the progression-free survival compared with placebo treatment (median: 20.6 versus 14.7 months), it was the first oral compound combined with lenalidomide and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy...
January 7, 2019: Leukemia & Lymphoma
Xue-Fei Chen, Shi-Cong Kou, Feng Xing
This research attempted to develop an environmentally-friendly functional building mortar by the combined use of agriculture wastes (agro-wastes) and construction wastes in magnesium oxychloride cement (MOC). The agro-wastes referred to corn stalk (CS) and saw dust (SD), which were used to improve the flexural properties of host cementitious material, whilst the construction wastes referred to recycled clay brick powder (CBP), which was employed to enhance compressive strength and water resistance. Moreover, tourmaline powder (TP) was added as a negative ion-inducing admixture, at a fixed dosage of 10% by weight of MgO, to bestow air-improving functions on the end products...
December 31, 2018: Materials
Meletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, Meral Beksac, Roman Hajek, Katja Christina Weisel, Hartmut Goldschmidt, Vladimir Maisnar, Philippe Moreau, Chang Ki Min, Agnieszka Pluta, Wee-Joo Chng, Martin Kaiser, Sonja Zweegman, Maria-Victoria Mateos, Andrew Spencer, Shinsuke Iida, Gareth Morgan, Kaveri Suryanarayan, Zhaoyang Teng, Tomas Skacel, Antonio Palumbo, Ajeeta B Dash, Neeraj Gupta, Richard Labotka, S Vincent Rajkumar
BACKGROUND: Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma. Ixazomib is ideally suited for maintenance therapy given its convenient once-weekly oral dosing and low toxicity profile. In this study, we aimed to determine the safety and efficacy of ixazomib as maintenance therapy following ASCT. METHODS: The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study took place in 167 clinical or hospital sites in 30 countries in Europe, the Middle East, Africa, Asia, and North and South America...
December 10, 2018: Lancet
Shinsuke Iida, Tohru Izumi, Nobuyuki Aotsuka, Takuya Komeno, Tadao Ishida, Kazutaka Sunami, Hiroshi Handa, Deborah Berg, Yoichi Kase, Junpei Soeda
Based on the outcomes of the TOURMALINE-MM1 trial-a global, randomized, double-blind, placebo-controlled phase III clinical study-the use of an oral proteasome inhibitor has been approved in combination with lenalidomide and dexamethasone (Rd) for the treatment of relapsed/refractory multiple myeloma (MM). In this study, we enrolled 41 Japanese patients, who constituted the safety population. The overall incidence of adverse events (AEs) was similar in IRd and placebo-Rd groups. AEs including thrombocytopenia, skin disorders (rash), vomiting, nausea, and diarrhea occurred more frequently in the IRd group than in the placebo-Rd group...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
David A Bushinsky, David M Spiegel, Jinwei Yuan, Suzette Warren, Jeanene Fogli, Pablo E Pergola
BACKGROUND AND OBJECTIVES: Patiromer is a sodium-free, nonabsorbed, potassium-binding polymer that uses calcium as the counter-exchange ion and is approved for treatment of hyperkalemia. The 4-week TOURMALINE study in patients with hyperkalemia previously demonstrated that patiromer administered once daily reduces serum potassium similarly when given with or without food. We report a prespecified exploratory efficacy analysis as well as a post hoc efficacy and safety analysis of the TOURMALINE study on circulating markers of mineral metabolism...
October 31, 2018: Clinical Journal of the American Society of Nephrology: CJASN
Kunio Kawamura, Noriko Konagaya, Yoshimi Maruoka
In a previous study, we have showed that the elongation of an alanine oligopeptide [L-alanyl-L-alanyl-L-alanyl-L-alanine ((Ala)4 )] to higher oligopeptides is enhanced by calcite and dolomite at 275°C, using a mineral-mediated hydrothermal flow reactor system. However, a problem during the use of hydrothermal flow reactor system was that some of the minerals, such as clay, could not be tested due to their clogging in the reactor. In this article, we attempted to analyze the scope of enhancement for the formation of L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanine ((Ala)5 ) and higher oligopeptides with different minerals including clay minerals for the elongation of alanine oligopeptide at 175°C...
November 2018: Astrobiology
Neeraj Gupta, Michael J Hanley, Cindy Xia, Richard Labotka, R Donald Harvey, Karthik Venkatakrishnan
Ixazomib, the first oral proteasome inhibitor, is approved in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy. Ixazomib is a selective, potent, and reversible inhibitor of the 20S proteasome, and preferentially binds to and inhibits the β5 chymotrypsin-like proteolytic site. Ixazomib absorption is rapid, with a median time to reach maximum plasma concentration of approximately 1 h post-dose. Ixazomib pharmacokinetics (PK) are adequately described by a three-compartment model (terminal half-life of 9...
August 17, 2018: Clinical Pharmacokinetics
Robert A Kloner, Coleman Gross, Jinwei Yuan, Ansgar Conrad, Pablo E Pergola
INTRODUCTION: Hyperkalemia (potassium >5.0 mEq/L) affects heart failure patients with renal disease regardless of the use of renin-angiotensin-aldosterone system inhibitors (RAASi). The open-label TOURMALINE study showed that patiromer, a sodium-free, nonabsorbed potassium binder, lowers serum potassium of hyperkalemic patients similarly when given with or without food; unlike prior studies, patients were not required to be taking RAASi. We conducted post hoc analyses to provide the first report of patiromer in patients not taking RAASi...
November 2018: Journal of Cardiovascular Pharmacology and Therapeutics
Jing-Yun Sun, Meng-Jie Fan, Ying-Wen Chen, She-Min Zhu, Shu-Bao Shen
The purpose of this study was to investigate the effect of different modified anodes on the microbial fuel cell(MFC) and the effect of MFC on the treatment of refractory wastewater. Based on a single room air cathode, the anode of MFC was modified by 0.10 g of tourmaline, 75% manganese bioxide/halloysite nanotube(MnO2 /HNT) and multi-walled carbon nanotube-carboxyl(MWCNT-COOH), respectively. The results showed that, the removal rate of purified terephthalic acid(PTA) was higher than 70%, and the chemical oxygen demand(COD) removal rate was more than 79% in MFC with different modified anodes...
July 8, 2017: Huan Jing Ke Xue= Huanjing Kexue
Nathaly De La Rosa, Per Kristiansson, E J Charlotta Nilsson, Linus Ros, Jan Pallon, Henrik Skogby
Proton-induced reaction (p,α) is one type of nuclear reaction analysis (NRA) suitable especially for light element quantification. In the case of lithium quantification presented in this work, accelerated protons with an energy about of 850 keV were used to induce the 7 Li(p,α)4 He reaction in standard reference and geological samples such as tourmaline and other Li-minerals. It is shown that this technique for lithium quantification allowed for measurement of concentrations down below one ppm. The possibility to relate the lithium content with the boron content in a single analysis was also demonstrated using tourmaline samples, both in absolute concentration and in lateral distribution...
2018: Journal of Radioanalytical and Nuclear Chemistry
Yahong Han, Shan Qiu, Hongyun Zeng, Fang Ma, Jue Wang, Yilun Qiu, Xuedi An
Tourmaline is a ring borosilicate with unique pyro-electricity and piezoelectricity values. Non-gem tourmaline is usually used as an environmental material. The short-term effects of ultrafine tourmaline particles on nitrogen removal performs microbial population dynamics. Key functional species in a sequencing batch reactor were investigated at 9 ± 1 °C. The investigation results showed that 1 g·L−1 ultrafine tourmaline particles could resist the effect of temperature shock on the metabolism of NH₄⁺-N and were beneficial to the restoration of the metabolism capacity of NH₄⁺-N...
June 17, 2018: International Journal of Environmental Research and Public Health
Chong Tan, Haoran Xu, Di Cui, Jinlong Zuo, Junsheng Li, Yubin Ji, Shan Qiu, Lin Yao, Ying Chen, Yingjie Liu
The effects of tourmaline on nitrogen removal performance and biofilm structures were comparatively investigated in two identical laboratory-scale sequencing batch biofilm reactors (SBBRs) (denoted SBBR1 and SBBR2) at different nitrogen loading rates (NLRs) varying from (0.24±0.01) to (1.26±0.02) g N/(L·day). SBBR1 was operated in parallel with SBBR2, but SBBR1 was filled with polyurethane foam loaded tourmaline (TPU) carriers and another (SBBR2) filled with polyurethane foam (PU) carriers. Results obtained from this study showed that the excellent and stable performance of SBBR1 was obtained...
May 2018: Journal of Environmental Sciences (China)
Dénes Száz, Gábor Horváth
According to a famous hypothesis, Viking sailors could navigate along the latitude between Norway and Greenland by means of sky polarization in cloudy weather using a sun compass and sunstone crystals. Using data measured in earlier atmospheric optical and psychophysical experiments, here we determine the success rate of this sky-polarimetric Viking navigation. Simulating 1000 voyages between Norway and Greenland with varying cloudiness at summer solstice and spring equinox, we revealed the chance with which Viking sailors could reach Greenland under the varying weather conditions of a 3-week-long journey as a function of the navigation periodicity Δ t if they analysed sky polarization with calcite, cordierite or tourmaline sunstones...
April 2018: Royal Society Open Science
Parameswaran Hari, Huamao Mark Lin, Yanyan Zhu, Deborah Berg, Paul G Richardson, Philippe Moreau
AIMS: The aim of this analysis was to assess healthcare resource utilization in the pivotal phase 3 TOURMALINE-MM1 study of the oral proteasome inhibitor ixazomib or placebo plus lenalidomide and dexamethasone (Rd) in relapsed and/or refractory multiple myeloma (RRMM). METHODS: In this double-blind, placebo-controlled, randomized study (NCT01564537), 722 patients with RRMM following 1-3 prior lines of therapy received Rd plus ixazomib (ixazomib-Rd; n = 360) or matching placebo (placebo-Rd; n = 362) until disease progression or unacceptable toxicity...
August 2018: Journal of Medical Economics
Xavier Leleu, Tamas Masszi, Nizar J Bahlis, Luisa Viterbo, Bartrum Baker, Peter Gimsing, Vladimir Maisnar, Olga Samoilova, Laura Rosiñol, Christian Langer, Kevin Song, Tohru Izumi, Charles Cleeland, Deborah Berg, Huamao Mark Lin, Yanyan Zhu, Tomas Skacel, Philippe Moreau, Paul G Richardson
TOURMALINE-MM1 is a phase III, randomized, double-blind, placebo-controlled study of ixazomib plus lenalidomide and dexamethasone (IRd) versus placebo-Rd in patients with relapsed/refractory multiple myeloma following 1-3 prior lines of therapy. The study met its primary endpoint, demonstrating significantly longer progression-free survival (PFS) in the IRd arm versus placebo-Rd arm (median 20.6 vs 14.7 months, hazard ratio 0.74, P = .01), with limited additional toxicity. Patient-reported health-related quality of life (HRQoL) was a secondary endpoint of TOURMALINE-MM1...
May 4, 2018: American Journal of Hematology
Michiko Machida, Shinichi Fukunaga, Takahito Hara
Ixazomib (Ninlaro® capsule) is an oral small molecule 20S proteasome inhibitor created by Millennium Pharmaceuticals, Inc (Takeda Oncology Company). Ubiquitin proteasome system is a major regulatory system for maintaining protein homeostasis, and an important mechanism for degrading proteins, such as those involved in proliferation regulation, cell cycle regulation and apoptosis, in cells. Ixazomib selectively and reversibly binds to the β5 subunit of the 20S proteasome, inhibits its chymotrypsin-like activity, and thereby accumulates ubiquitinated proteins...
2018: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
Weili Jia, Cuiping Wang, Chuanxin Ma, Jicheng Wang, Hongwen Sun
Element migration and physiological response in Lactuca sativa upon co-exposure to tourmaline (T) and dissolved humic acids (DHAs) were investigated. Different fractions of DHA1 and DHA4 and three different doses of T were introduced into Hoagland's solution. The results indicated that T enhanced the contents of elements such as N and C, Si and Al in the roots and shoots. The correlation between TF values of Si and Al (R2  = 0.7387) was higher than that of Si and Mn (R2  = 0.4961) without the presence of DHAs...
June 2018: Environmental Science and Pollution Research International
Xavier Armoiry, Martin Connock, Alexander Tsertsvadze, Ewen Cummins, G J Melendez-Torres, Pam Royle, Aileen Clarke
Ixazomib is an oral proteasome inhibitor used in combination with lenalidomide plus dexamethasone (IXA-LEN-DEX) and licensed for relapsed or refractory multiple myeloma. As part of a single technology appraisal (ID807) undertaken by the National Institute of Health and Care Excellence, the Evidence Review Group, Warwick Evidence was invited to independently review the evidence submitted by the manufacturer of ixazomib, Takeda UK Ltd. The main source of clinical effectiveness data about IXA-LEN-DEX came from the Tourmaline-MM1 randomized controlled trial in which 771 patients with relapsed or refractory multiple myeloma received either IXA-LEN-DEX or placebo-LEN-DEX as their second-, third-, or fourth-line treatment...
September 2018: PharmacoEconomics
Laurent Garderet, Jacob P Laubach, Anne-Marie Stoppa, Parameswaran Hari, Michele Cavo, Heinz Ludwig, María-Victoria Mateos, Katarina Luptakova, Jianchang Lin, Godwin Yung, Helgi van de Velde, Deborah Berg, Philippe Moreau, Paul G Richardson
No abstract text is available yet for this article.
September 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"